血塞通对心绞痛患者介入治疗后血清同型半胱氨酸等的影响  

Effects of Xuesaitong on serum homocysteine in angina pectoris patients after percutaneous coronary intervention

作　　者：张彩平 彭昱东[2] 吴红军[3] ZHANG Caiping;PENG Yudong;WU Hongjun(Department of Cardiovascular Medicine,Laohekou First Hospital,Laohekou 441800,China;Department of Cardiovascular Medicine,Wuhan Union Hospital,Wuhan 431800,China;Department of Emergency,Wuhan Union Hospital,Wuhan 431800,China)

机构地区：[1]老河口市第一医院心血管内科,老河口441800 [2]武汉协和医院心血管内科,武汉431800 [3]武汉协和医院急诊科,武汉431800

出　　处：《西北药学杂志》2022年第2期154-158,共5页Northwest Pharmaceutical Journal

摘　　要：目的探讨血塞通对冠心病心绞痛患者介入治疗后血清同型半胱氨酸(Hcy)、过氧化脂质(LPO)和血小板膜蛋白-140(GMP-140)水平的影响。方法选取入院行PCI治疗后的冠心病心绞痛患者280例作为研究对象,采用随机数字表法分为研究组与对照组,每组140例。对照组PCI术后采取常规药物治疗,研究组在对照组治疗的基础上加用血塞通治疗。比较2组治疗效果、症状缓解情况、心功能指标[心输出量(CO)、每搏输出量(SV)、左室射血分数(LVEF)]、血清生化指标[Hcy、LPO、超氧化物歧化酶(SOD)]、血小板功能指标[GMP-140、血浆内皮素(ET)、血小板最大聚集率(MPRA)]水平及不良反应发生情况。结果研究组治疗后总有效率为91.43%,高于对照组的82.86%(P<0.05);研究组治疗后心绞痛持续时间、发病频率较对照组降低(P<0.05);研究组治疗后LVEF、CO和SV水平较对照组升高(P<0.05);研究组治疗后Hcy、LPO、GMP-140、ET和MPRA水平较对照组降低,SOD水平升高(P<0.05);研究组治疗期间不良反应总发生率为11.43%,与对照组的8.57%比较差异无统计学意义(P>0.05)。结论血塞通对冠心病心绞痛患者介入后治疗可明显改善患者的心功能,有效缓解相关症状,减轻患者炎症反应及氧化应激反应,改善凝血功能,对该病具有良好的治疗效果。Objective To explore the effects of Xuesaitong on the levels of serum homocysteine(Hcy),lipid peroxidation(LPO)and granule membrane glycoprotein of platelet-140(GMP-140)in patients with angina pectoris of coronary heart disease(CHD)after percutaneous coronary intervention(PCI).Methods A total of 280 patients with CHD angina pectoris who underwent PCI in a hospital were enrolled as the research objects.They were divided into study group and control group by random number table method,140 cases in each group.After PCI,the control group were treated with routine drugs,while the study group were treated with Xuesaitong on the routine basis.The curative effect,symptoms remission,levels of cardiac function indexes[cardiac output(CO),stroke volume(SV),left ventricular ejection fraction(LVEF)],serum biochemical indexes[Hcy,LPO,superoxide dismutase(SOD)]and platelet function indexes[GMP-140,plasma endothelin(ET),maximum platelet aggregation rate(MPRA)],and adverse reactions were compared between the 2 groups.Results After treatment,the total response rate in study group was higher than that in control group(91.43%vs.82.86%)(P<0.05).After treatment,the duration and frequency of angina pectoris onset in study group were lower than those in control group(P<0.05).After treatment,the levels of LVEF,CO and SV in the study group were higher than those in control group(P<0.05),the levels of Hcy,LPO,GMP-140,ET and MPRA were lower than those in control group,and SOD level was higher than that in control group(P<0.05).There was no significant difference in the total incidence of adverse reactions during the treatment between the study group and the control group(11.43%vs.8.57%)(P>0.05).Conclusion Xuesaitong can significantly improve the cardiac function of patients with CHD angina pectoris after PCI,effectively alleviate related symptoms,inflammatory response and oxidative stress response,and improve the coagulation function,with good curative effect on the disease.

关 键 词：血塞通 心绞痛 同型半胱氨酸(Hcy) 过氧化脂质(LPO) 血小板膜蛋白-140(GMP-140) 

分 类 号：R972[医药卫生—药品]